Efficacy of six therapies for chronic hepatitis B

Table 1 HBsAg negative cases and anti-HBs positive cases after treatment

Group	(n)	End of treatment		3 mo after treatment		9 mo after treatment
		HBsAg(-)	Anti-HBs(+)	HBsAg(-)	Anti-HBs(+)	HBsAg(-)	Anti-HBs(+)
I	45	1	0	2	1	2	1
II	63	2	0	2	1	2	2
III	52	1	0	2	1	1	1
IV	42	3	2	3	3	2	3
V	58	3	0	3	2	2	2
VI	42	0	0	0	0	0	0

Table 2 HBeAg negative rate (%), anti-HBe positive rate (%) and HBV-DNA negative rate (%) after treatment

Group	(n)	End of treatment			3 mo after treatment			9 mo after treatment
		HBsAg(-)	Anti-HBs(+)	DNA(-)	HBsAg(-)	Anti-HBs(+)	DNA(-)	HBsAg(-)	Anti-HBs(+)	DNA(-)
I	45	44.4	33.3	46.7	46.7	40.0	48.8	42.2	35.6	40.0
II	63	53.9	36.7	55.6	53.9	37.9	57.1	44.4	38.1	40.6
III	52	51.9	25.0	55.6	50.0	28.8	52.8	30.8	28.8	32.7
IV	42	61.9	54.8b	71.4	64.9	56.8b	75.7	62.1d	62.1b	72.4
V	58	55.2	37.9	70.7	56.9	41.1	74.1	57.7a	41.4	48.3
VI	42	14.3	11.9	14.3	19.0	16.3	19.0	16.7	16.7	16.7

^bP < 0.01, group IV vs other groups;

^dP < 0.01, group IV vs group III; and

^aP < 0.05, group V vs group III.